Rare tumors of the colon and rectum: a national review

Kang, Hakjung; O’Connell, Jessica; Leonardi, Michael J.; Maggard, Melinda A.; McGory, Marcia L.; Ko, Clifford Y.

doi:10.1007/s00384-006-0145-2

Cited by 135 publications

(107 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also confirmed previous observations that tumor size and muscle layer invasion are important predictive criteria in assessing the malignant nature of rectal carcinoids 1,2,[14][15][16][17][18][19]23,28,33,34 and that patients with typical and atypical bronchopulmonary carcinoid tumors display significantly different metastatic possibilities and 10-year postoperative survival rates. [35][36][37][38] In addition, we demonstrated that thymic carcinoids, also known as welldifferentiated neuroendocrine carcinomas, usually bear high risks for recurrence, metastasis, and tumor-associated death, and patients with thymic carcinoids have a worse prognosis compared with bronchial carcinoids.…”

Section: Metastases and Survivalsupporting

confidence: 90%

“…They are derived from the enterochromaffin/neuroendocrine cell compartments, which usually are scattered throughout the body. [1][2][3][4][5][6][7] Carcinoid tumors represents approximately 0.49% of all malignancies, and the incidence is estimated from 0.65 to 4.48 per 100,000 population per year. [7][8][9][10][11][12] The gastrointestinal tract and respiratory system usually are the most common sites for carcinoid tumors, reflecting the high density of enterochromaffin/neuroendocrine cells in the mucosa of the digestive system and the respiratory epithelium.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A 35‐year retrospective study of carcinoid tumors in Taiwan

Hsu

Li³

et al. 2007

Cancer

View full text Add to dashboard Cite

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) represent useful models for studying multiple myeloma precursor disease, and for developing early intervention strategies. Administering a 4g dose of curcumin, we performed a randomised, double‐blind placebo‐controlled cross‐over study, followed by an open‐label extension study using an 8g dose to assess the effect of curcumin on FLC response and bone turnover in patients with MGUS and SMM. 36 patients (19 MGUS and 17 SMM) were randomised into two groups: one received 4g curcumin and the other 4g placebo, crossing over at 3 months. At completion of the 4g arm, all patients were given the option of entering an open‐label, 8g dose extension study. Blood and urine samples were collected at specified intervals for specific marker analyses. Group values are expressed as mean ± 1 SD. Data from different time intervals within groups were compared using Student's paired t‐test. 25 patients completed the 4g cross‐over study and 18 the 8g extension study. Curcumin therapy decreased the free light‐chain ratio (rFLC), reduced the difference between clonal and nonclonal light‐chain (dFLC) and involved free light‐chain (iFLC). uDPYD, a marker of bone resorption, decreased in the curcumin arm and increased on the placebo arm. Serum creatinine levels tended to diminish on curcumin therapy. These findings suggest that curcumin might have the potential to slow the disease process in patients with MGUS and SMM. Am. J. Hematol. 87:455–460, 2012. © 2012 Wiley Periodicals, Inc.

show abstract

Section: Metastases and Survivalsupporting

confidence: 90%

mentioning

confidence: 99%

A 35‐year retrospective study of carcinoid tumors in Taiwan

Hsu

Li³

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…Similar results in a Tunisian study where CRC adenocarcinoma was well differentiated in 46% of cases, moderately differentiated in 33.3% of cases and undifferentiated in 11.3% of cases [55]. Our series and the Moroccan series report the same results [47,56,57].…”

Section: Discussion:-supporting

confidence: 91%

Colorectal Cancer in Marrakech Tensift Elhaouz, Epidemiological and Anatomopathological Aspects, About 2584 Cases in 19 Years.

Rabbani¹,

Hakam²,

Narjis³

et al. 2017

IJAR

View full text Add to dashboard Cite

“…From a review of the population study, the overall 5-year survival for rectal SCC was found to be 48.9% compared with 62.1% for adenocarcinoma. When localised, the 5 years OS was 73.7% versus 91.8% for adenocarcinoma, with 31.3% versus 65.8% for regional and 20.8% versus 8.8% for metastatic disease (17) .…”

Section: Discussionmentioning

confidence: 94%

Primary Squamous Cell Carcinoma of the Rectum Case Report with Literature Review

Abbassi

Touil²,

Echchikhi³

et al. 2017

IAM

View full text Add to dashboard Cite

Background: Squamous cell carcinoma of the rectum is a distinct entity. We report a rare case of squamous cell carcinoma of the middle and low rectum. Case presentation: The patient was a 60-year-old man who presented with a history of rectal Bleeding, constipation and pelvic painless. Rectoscopy and Colonoscopy revealed a polypoid tumour of the middle and low rectum. Biopsies of this mass revealed a poorly differentiated squamous cell carcinoma of the rectum. Pelvic Magnetic Resonance Imaging scan showed a polypoid, irregular and circumferential tumor in the middle and low rectum extending in length on 95mm. CT scan of the chest, abdomen and pelvis was negative for distal metastases. The patient received combined chemo-radiation. Overall treatment time was 45 days. After 6 weeks of the end of treatment, the revaluation clinical tests by pelvic magnetic resonnance imaging showed a poor response. After 3 months, Positron Emission Tomography with Fluorodeoxyglucose demonstrated a little hypermetabolic area with maximum standard up take value of 6,7 in the low rectum. Patient underwent a surgical resection. The postoperative histopathological findings were non specific and chronic inflammatory changes. At the time this report was written, the patient had 18 months of follow-up. No evidence of malignacy is found. Conclusion: Squamous cell carcinoma of the rectum is a distinct entity. Chemoradiation should be chosen as the first-line therapy for suqamous cell carcinoma of the rectum. However,a large study will be required to establish a safe and effective regimen.

show abstract

Rare tumors of the colon and rectum: a national review

Abstract: This study provides the first population-based analysis of the epidemiology, tumor characteristics, and survival rates for rare CRC.

Cited by 135 publications

References 20 publications

A 35‐year retrospective study of carcinoid tumors in Taiwan

A 35‐year retrospective study of carcinoid tumors in Taiwan

Colorectal Cancer in Marrakech Tensift Elhaouz, Epidemiological and Anatomopathological Aspects, About 2584 Cases in 19 Years.

Primary Squamous Cell Carcinoma of the Rectum Case Report with Literature Review

Contact Info

Product

Resources

About